Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX 4291 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX 4291 (Part A) | EXPERIMENTAL | Participants will be administered single ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part B) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part C) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered single or multiple ascending doses of placebo. |
| Name | Type | Description |
|---|---|---|
| MBX 4291 | DRUG | MBX 4291 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo: Placebo will be administered subcutaneously (SC) |
Inclusion Criteria: * Age of \>18 to ≤65 years at the time of signing the informed consent. * Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline. * Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline. Exclusi...
Top 20 of 32 competitors
MBX 4291 is an investigational small molecule being developed for the treatment of obesity. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and effectiveness in clinical trials.
MBX 4291 is being developed by MBX Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MBX. The company is conducting clinical trials to evaluate the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics in adult participants with obesity.
MBX 4291 is in Phase 1 clinical development. The drug is investigational and has not been approved by the FDA or any other regulatory agency. It is currently being studied in a Phase 1 trial to assess its safety, tolerability, and how the body processes the drug in adults with obesity.
MBX 4291 is being evaluated in a Phase 1 clinical trial registered as NCT07142707. This study is recruiting 124 adult participants with obesity in the United States. The trial is randomized, double-blind, and placebo-controlled, and it is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MBX 4291.
No, MBX 4291 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in a clinical trial to evaluate its safety and tolerability in adults with obesity, but it has not yet received regulatory approval for any use.